Get started
Work

Immunotherapy in anaplastic thyroid cancer.

Year: 2020
Type: article
Abstract: Anaplastic thyroid cancer (ATC) is one of the worst human malignancies, with an associated median survival of only 5 months. It is resistant to conventional thyroid cancer therapies, including radioiodine and thyroid-stimulating hormone suppression. Cancer immunotherapy has emerged over the past few decades as a transformative approach to treating a wide variety of cancers. However, immunotherapy for ATC is still in the experimental stage. This review will cover several strategies of immunotherapy and discuss the possible application of these strategies in the treatment of ATC (such as targeted therapy for tumor-associated macrophages, cancer vaccines, adoptive immunotherapy, monoclonal antibodies and immune checkpoint blockade) with the hope of improving the prognosis of ATC in the future.
Authors: Maoguang Ma, Bo Lin, Mingdian Wang, Xiaoli Liang, Lei Su, Okenwa Okose, Weiming Lv, Jie Li
Institutions: The First Affiliated Hospital, Sun Yat-sen University, Sun Yat-sen University, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Massachusetts Eye and Ear Infirmary, Harvard University, Texas A&M University
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W3026726498
FWCI: 3.697
Cites: 111
Cited by: 29
Related to: 10